Akebia Therapeutics (AKBA) Net Cash Flow Growth (3y) (2016 - 2026)
Akebia Therapeutics (AKBA) Net Cash Flow Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.74 Bn | 86.88 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.87 Bn | 32.13 Bn | 1.97 Bn | 32.03% |
| 3 | Zoetis | 32.28 Bn | 30.34 Bn | 1.62 Bn | 28.99% |
| 4 | Takeda Pharmaceutical | 27.51 Bn | 23.45 Bn | 4.39 Bn | 37.89% |
| 5 | United Therapeutics | 23.14 Bn | 20.98 Bn | 648.10 Mn | -49.94% |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.25 Bn | 18.44 Bn | 1.16 Bn | 37.74% |
| 8 | Neurocrine Biosciences | 17.89 Bn | 16.57 Bn | 800.70 Mn | -41.05% |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | -62.71% |
| 10 | Akebia Therapeutics | 341.85 Mn | 179.25 Mn | 41.25 Mn | 12.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.83% |
| Dec 31, 2025 | 32.70% |
| Sep 30, 2025 | 222.60% |
| Jun 30, 2025 | 40.62% |
| Mar 31, 2025 | 33.57% |
| Dec 31, 2024 | 32.21% |
| Sep 30, 2024 | 48.38% |
| Jun 30, 2024 | 24.80% |
| Mar 31, 2024 | -26.84% |
| Dec 31, 2023 | -27.25% |
| Sep 30, 2023 | 54.61% |
| Jun 30, 2023 | -26.69% |
| Mar 31, 2023 | -1.55% |
| Dec 31, 2022 | -61.68% |
| Sep 30, 2022 | -71.00% |
| Jun 30, 2022 | -48.17% |
| Mar 31, 2022 | 37.79% |
| Dec 31, 2021 | -0.30% |
| Sep 30, 2021 | -231.12% |
| Jun 30, 2021 | -44.60% |